RT Journal Article
T1 Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
A1 Idahl, Annika
A1 Le Cornet, Charlotte
A1 Gonzalez Maldonado, Sandra
A1 Waterboer, Tim
A1 Bender, Noemi
A1 Tjønneland, Anne
A1 Hansen, Louise
A1 Boutron-Ruault, Marie-Christine
A1 Fournier, Agnes
A1 Kvaskoff, Marina
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Valanou, Elisavet
A1 Peppa, Eleni
A1 Palli, Domenico
A1 Agnoli, Claudia
A1 Mattiello, Amalia
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Onland-Moret, N Charlotte
A1 Gram, Inger T
A1 Weiderpass, Elisabete
A1 Quiros, Jose R
A1 Duell, Eric J
A1 Sanchez-Perez, Maria-Jose
A1 Chirlaque, Maria-Dolores
A1 Barricarte, Aurelio
A1 Gil, Leire
A1 Brändstedt, Jenny
A1 Riesbeck, Kristian
A1 Lundin, Eva
A1 Khaw, Kay-Tee
A1 Perez-Cornago, Aurora
A1 Gunter, Marc J
A1 Dossus, Laure
A1 Kaaks, Rudolf
A1 Fortner, Renee T
K1 Chlamydia trachomatis
K1 Mycoplasma genitalium
K1 herpes simplex virus
K1 human papillomavirus
K1 ovarian cancer
AB A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation after sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead-based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (CI) comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95% CI = 1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1) was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid EOC (2.35 [1.24-4.43]). The findings of our study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might promote the development of endometrioid disease.
PB John Wiley & Sons, Inc.
YR 2020
FD 2020-02-19
LK http://hdl.handle.net/10668/15317
UL http://hdl.handle.net/10668/15317
LA en
NO Idahl A, Le Cornet C, González Maldonado S, Waterboer T, Bender N, Tjønneland A, et al.  Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort. Int J Cancer. 2020 Oct 15;147(8):2042-2052.
NO Anna and Edwin Berger Foundation;Associazione Italiana per la Ricerca sul Cancro;Bundesministerium für Bildung und Forschung;Cancer Research UK, Grant/Award Number:14136; C570/A16491; C8221/A19170;Cancerfonden, Grant/Award Number: CAN2016/545; County Councils of Skåne andVästerbotten; Danish Cancer Society;Deutsche Krebshilfe; DeutschesKrebsforschungszentrum; Dutch Ministry ofPublic Health, Welfare and Sports (VWS);Dutch Prevention Funds; EuropeanCommission (DG-SANCO); FP7 Ideas:European Research Council, Grant/AwardNumber: ERC-2009-AdG 232997; HealthResearch Fund (FIS), Grant/Award Numbers:PI13/00061, PI13/01162; Hellenic HealthFoundation; Institut Gustave Roussy; InstitutNational de la Santé et de la RechercheMédicale; Instituto de Salud Carlos III, Grant/Award Number: RD06/0020; InternationalAgency for Research on Cancer; Ligue Contrele Cancer; LK Research Funds; Malmö HospitalCancer Foundation; Medical Research Council,Grant/Award Numbers: 1000143, MR/M012190/1; Mutuelle Générale de l'EducationNationale; National Research Council Italy;Netherlands Cancer Registry; NordForsk;Nordic Centre of Excellence programme onFood, Nutrition and Health; RegionalGovernments of Andalucía, Asturias, BasqueCountry, Murcia and Navarra; StatisticsNetherlands; Swedish Research Council; TheCancer Research Foundation in NorthernSweden; The County Council of Västerbotten,Sweden; Wereld Kanker Onderzoek Fonds;Zorg Onderzoek Nederland
DS RISalud
RD Apr 7, 2025